Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Sulfurous Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfurous Acid SCHEMBL9436266 | 1.00 | — | — | |
| Sulfurous Acid SCHEMBL27391564 | 1.00 | — | — | |
| Sulfurous Acid SCHEMBL1093823 | 1.00 | CA1 (0.75) | CA1CA2 | |
| Sulfurous Acid SCHEMBL3884261 | 1.00 | CA1 (0.75) | CA1CA2 | |
| Sulfurous Acid SCHEMBL3186682 | 1.00 | — | — | |
| Sulfurous Acid SCHEMBL8003764 | 1.00 | — | — | |
| Sulfurous Acid SCHEMBL9117249 | 1.00 | CA1 (0.75) | CA1CA2 | |
| Sulfurous Acid SCHEMBL28048784 | 1.00 | CA1 (0.75) | CA1CA2 | |
| Sulfurous Acid SCHEMBL23249641 | 0.94 | CA1 (0.67) | CA1CA2 | |
| Sulfurous Acid SCHEMBL28396462 | 0.94 | CA1 (0.67) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250343500-A1 | FRONTSHEETS FOR PHOTOVOLTAIC MODULES | GAF Energy LLC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250141395-A1 | BACKSHEETS FOR PHOTOVOLTAIC MODULES | GAF Energy LLC (US) | 2025-05-01 | — | — | US | disclosed |
| US-20170218310-A1 | Laundry Scent Booster | COLGATE-PALMOLIVE COMPANY (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170222080-A1 | SOLAR CELL MODULE, METHOD OF MANUFACTURING THE SAME, AND PHOTOVOLTAIC POWER GENERATION SYSTEM | SHARP KK (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-3176833-A1 | SOLAR CELL MODULE, METHOD FOR MANUFACTURING SAME AND SOLAR PHOTOVOLTAIC POWER GENERATION SYSTEM | Sharp Kabushiki Kaisha (JP) | 2017-06-07 | — | — | EP | disclosed |
| US-20100317712-A1 | Estrogen Agonists/Antagonists For Preventing Breast Cancer | CAMERON KIMBERLY O | 2010-12-16 | — | — | US | disclosed |
| US-20100019197-A1 | DEOXIDANT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-01-28 | — | — | US | disclosed |
| US-20080230744-A1 | Deoxidant Composition | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| US-RE39558-E1 | 5-Substituted-6-cyclic-5,6,7,8-tetrahydronaphthalen 2-ol compounds which are useful for treating osteoporosis | PFIZER INC. (US) | 2007-04-10 | — | — | US | disclosed |
| CN-1942240-A | Oxygen absorber composition | TAKASAGO PERFUMERY CO LTD (JP) | 2007-04-04 | — | — | CN | disclosed |
| US-20020132816-A1 | Estrogen agonists/antagonists for preventing breast cancer | CAMERON KIMBERLY O (US) | 2002-09-19 | — | — | US | disclosed |
| US-6441193-B1 | INTERMEDIATES SUCH AS 1-(2-(4-(6-METHOXY-3,4-DIHYDRONAPHTHA-LEN-1-YL)PHENOXY)ETHYL)PYRROLIDINE AND COMPOUNDS SUCH AS CIS-6-PHENYL-5-(4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL)-5,6,7,8 -TETRAHYDRONAPHTHALEN-2-OL, HYDROBROMIDE SALT | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| EP-0802910-B1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-1151998-A1 | Estrogen agonists/antagonists | PFIZER INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-20010025051-A1 | Estrogen agonists/antagonists for preventing breast cancer | CAMERON KIMBERLY O (US) | 2001-09-27 | — | — | US | disclosed |
| US-6204286-B1 | 8-(P-(PYRROLIDINYLALKOXY)PHENYL)TETRAHYDRONAPHTHOLS | PFIZER INC | 2001-03-20 | — | — | US | disclosed |
| CN-1278715-A | Concentrating liquid absorption in the central portion of a breathable absorbent article | PROCTER & GAMBLE (US) | 2001-01-03 | — | — | CN | disclosed |
| EP-1004306-A2 | Estrogen agonists/antagonists | Pfizer Products Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-0802910-A1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER INC. (US) | 1997-10-29 | — | — | EP | disclosed |
| WO-1996021656-A1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER, INC. (US) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025051-A1 | Estrogen agonists/antagonists for preventing breast cancer | GPER1, ESR1, BRCA1 | CA1 2816/4885CA2 3959/4885 |
| US-20100317712-A1 | Estrogen Agonists/Antagonists For Preventing Breast Cancer | ESR1, GPER1, ESR2 | CA1 3258/4885CA2 3921/4885 |
| US-20020132816-A1 | Estrogen agonists/antagonists for preventing breast cancer | GPER1, ESR1, BRCA1 | CA1 2816/4885CA2 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.